| Tag |
First Indicator |
Second Indicator |
Subfields |
| LEADER |
00000cam a2200000Ia 4500 |
| 001 |
in00003500331 |
| 006 |
m o d |
| 007 |
cr cn||||||||| |
| 008 |
030617s2003 njua ob 001 0 eng d |
| 005 |
20260421164217.4 |
| 019 |
|
|
|a 606939419
|a 649991164
|
| 020 |
|
|
|a 1592594018 (electronic bk.)
|
| 020 |
|
|
|a 9781592594016 (electronic bk.)
|
| 020 |
|
|
|z 0896039307 (alk. paper)
|
| 020 |
|
|
|z 9780896039308 (alk. paper)
|
| 035 |
|
|
|a (OCoLC)52442956
|z (OCoLC)606939419
|z (OCoLC)649991164
|
| 040 |
|
|
|a N$T
|b eng
|e pn
|c N$T
|d YDXCP
|d OCLCG
|d OCLCQ
|d E7B
|d IDEBK
|d OCLCQ
|d TUU
|d OCLCQ
|d TNF
|d OCLCQ
|d ZCU
|d OCLCO
|d GW5XE
|d OCLCE
|d OCLCQ
|d UtOrBLW
|
| 042 |
|
|
|a dlr
|
| 049 |
|
|
|a TXAM
|
| 050 |
|
4 |
|a RC271.C5
|b C367 2003eb
|
| 060 |
|
4 |
|a QZ 267
|b C393 2003
|
| 072 |
|
7 |
|a MED
|x 062000
|2 bisacsh
|
| 072 |
|
7 |
|a HEA
|x 039030
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.99/4061
|2 21
|
| 245 |
0 |
0 |
|a Cell cycle inhibitors in cancer therapy :
|b current strategies /
|c edited by Antonio Giordano and Kenneth J. Soprano.
|
| 264 |
|
1 |
|a Totowa, N.J. :
|b Humana Press,
|c [2003]
|
| 264 |
|
4 |
|c ©2003
|
| 300 |
|
|
|a 1 online resource (x, 326 pages) :
|b illustrations.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Cancer drug discovery and development
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 520 |
|
|
|a The molecular approach to disease continues to yield a tremendous amount of new information about those aspects of cellular replication that we use to understand, prevent, diagnose, and cure cancer. In Cell Cycle Inhibitors in Cancer Therapy: Current Strategies, recognized clinicians and investigators review in a comprehensible and user-friendly style all the latest information about the molecular biology of cell-cycle control and demonstrate its clinical relevance to understanding neoplastic diseases. Topics range from Cdk inhibitors and cell cycle regulators to the prognostic value of p27 and tumor-suppressor genes as diagnostic tools. Actual case studies show how the new molecular understanding has produced such drugs as Flavopiridol and Sulindac. Up-to-date and richly instructive, Cell Cycle Inhibitors in Cancer Therapy: Current Strategies brings all the recent critical research findings to bear on clinical practice, and clearly shows their powerful impact on the diagnostics, prognostics, and therapeutics of cancer, AIDS, and cardiovascular disease.
|
| 538 |
|
|
|a Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002.
|u http://purl.oclc.org/DLF/benchrepro0212
|5 MiAaHDL
|
| 583 |
1 |
|
|a digitized
|c 2010
|h HathiTrust Digital Library
|l committed to preserve
|2 pda
|5 MiAaHDL
|
| 588 |
|
|
|a Description based on print version record.
|
| 500 |
|
|
|a Electronic resource.
|
| 650 |
|
0 |
|a Cancer
|x Chemotherapy.
|
| 650 |
|
0 |
|a Cell cycle
|x Effect of drugs on.
|
| 650 |
|
0 |
|a Cancer cells
|x Growth
|v Regulations.
|
| 650 |
1 |
2 |
|a Cell Cycle
|x drug effects.
|
| 650 |
1 |
2 |
|a Neoplasms
|x drug therapy.
|
| 650 |
2 |
2 |
|a Cell Cycle Proteins
|x antagonists & inhibitors.
|
| 650 |
2 |
2 |
|a Enzyme Inhibitors
|x therapeutic use.
|
| 650 |
2 |
2 |
|a Genes, Tumor Suppressor.
|
| 650 |
|
7 |
|a MEDICAL
|x Oncology.
|2 bisacsh
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x Cancer.
|2 bisacsh
|
| 650 |
|
7 |
|a Neoplasias (quimioterapia)
|2 larpcal
|
| 650 |
|
7 |
|a Ciclo celular (efeitos de drogas)
|2 larpcal
|
| 650 |
|
7 |
|a Quimioterapia.
|2 larpcal
|
| 655 |
|
7 |
|a Electronic books.
|2 local
|
| 700 |
1 |
|
|a Giordano, Antonio,
|c MD.
|
| 700 |
1 |
|
|a Soprano, Kenneth J.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 776 |
1 |
8 |
|i Print version:
|t Cell cycle inhibitors in cancer therapy.
|d Totowa, N.J. : Humana Press, ©2003
|z 0896039307
|w (DLC) 2002027315
|w (OCoLC)50149627
|
| 830 |
|
0 |
|a Cancer drug discovery and development.
|
| 856 |
4 |
0 |
|u http://proxy.library.tamu.edu/login?url=https://link.springer.com/10.1007/978-1-59259-401-6
|z Connect to the full text of this electronic book
|t 0
|
| 994 |
|
|
|a 92
|b TXA
|
| 999 |
|
|
|a MARS
|
| 999 |
f |
f |
|s 8dedcfa5-9000-366c-ab8f-a7a624ce3c94
|i 64da5768-6afd-3c3a-a369-3c2f59d139d0
|t 0
|
| 952 |
f |
f |
|a Texas A&M University
|b College Station
|c Electronic Resources
|s www_evans
|d Available Online
|t 0
|e RC271.C5 C367 2003eb
|h Library of Congress classification
|
| 998 |
f |
f |
|a RC271.C5 C367 2003eb
|t 0
|l Available Online
|